Brought to you by 
AlloVir gets $121mm via Series B
28 May 2019
Executive Summary
AlloVir Inc. (formerly ViraCyte; developing cell therapies for virus-associated diseases) raised $121mm through its Series B financing led by Fidelity Management and Research Co., which was joined by Gilead Sciences (adds a board observer), F2 Ventures (adds a director), Redmile Group, Invus, EcoR1 Capital, Samsara BioCapital, and Leerink Partners. AlloVir will use the proceeds for Phase III trials of its lead antiviral program Viralym-M (ALVR105).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com